Spravato, a depression treatment derived from club drug ketamine, was looking like a dud. Its recent success now shows a path forward for psychedelic-based medicines.
Spravato, a depression treatment derived from club drug ketamine, was looking like a dud. Its recent success now shows a path forward for psychedelic-based medicines. WSJ.com: US Business